Author:
Yang Yongkun,Huang Zhen,Yuan Mingming,Rui Jinqiu,Chen Rongrong,Jin Tao,Sun Yang,Deng Zhiping,Shan Huachao,Niu Xiaohui,Liu Weifeng
Abstract
AbstractOsteosarcoma is a heterogeneous disease with regard to its chemotherapy response and clinical outcomes. This study aims to investigate the genomic and transcriptomic characteristics related to pre-operative chemotherapy response. Samples from 25 osteosarcoma patients were collected to perform both whole exome and transcriptome sequencing. Osteosarcoma had significant amount of chromosomal copy number variants (CNVs). Chemotherapy responders showed the higher chromosomal CNV burden than non-responders (p = 0.0775), but the difference was not significant. The percentage of COSMIC signature 3, associated with homologous recombination repair deficiency, was higher in responders (56%) than in non-responders (45%). Transcriptomic analysis suggested that 11 genes were significantly up-regulated in responders and 18 genes were up-regulated in non-responders. Both GSEA and KEGG enrichment analysis indicted that four pathways related to cardiomyopathy were up-regulated in responders, while neuroactive ligand − receptor interaction was up-regulated in non-responders. Finally, a previously published chemoresistant model was validated using our dataset, with the area under the curve of 0.796 (95% CI, 0.583–1.000). Osteosarcoma had the heterogeneous mutational profile with frequent occurrence of CNVs. Transcriptomic analysis identified several signaling pathways associated with chemotherapy responsiveness to osteosarcoma. Transcriptomic signatures provides a potential research direction for predicting the chemotherapy response.
Funder
Beijing Natural Science Foundation
Beijing Hospitals Authority Youth Programme
Beijing Jishuitan Hospital Elite Young Scholar Programme
Beijing JST Research Funding
National Key R&D Program of China
Beijing Municipal Administration of Hospitals Incubating Program
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Cole, S., Gianferante, D. M., Zhu, B. & Mirabello, L. Osteosarcoma: A surveillance, epidemiology, and end results program-based analysis from 1975 to 2017. Cancer 128, 2107–2118. https://doi.org/10.1002/cncr.34163 (2022).
2. Ritter, J. & Bielack, S. S. Osteosarcoma. Ann. Oncol. 21(7), 320–325. https://doi.org/10.1093/annonc/mdq276 (2010).
3. Bacci, G. et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106, 1154–1161. https://doi.org/10.1002/cncr.21724 (2006).
4. Bishop, M. W. et al. Assessing the prognostic significance of histologic response in osteosarcoma: A comparison of outcomes on CCG-782 and INT0133-A report from the children’s oncology group bone tumor committee. Pediatr. Blood Cancer 63, 1737–1743. https://doi.org/10.1002/pbc.26034 (2016).
5. Huvos, A. G., Rosen, G. & Marcove, R. C. Primary osteogenic sarcoma: Pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch. Pathol. Lab. Med. 101, 14–18 (1977).